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Adipose tissue expresses cytokines which inhibit insulin signalling pathways 
in liver and muscle. Obesity also results in impairment of endothelium-
dependent vasodilatation to insulin. We propose a vasoregulatory role for 
local deposits of fat around the origin of arterioles supplying skeletal muscle. 
Isolated first order arterioles from rat cremaster muscle are under dual 
regulation by insulin, which activates both endothelin-1 mediated 
vasoconstriction and nitric oxide mediated vasodilatation. In obese rat 
arterioles, insulin-stimulated nitric oxide synthesis is impaired, resulting in 
unopposed vasoconstriction. We propose this to be the consequence of 
production of the adipocytokine tumour necrosis factor-α from the cuff of fat 
seen surrounding the origin of the arteriole in obese rats - a depot to which 
we ascribe a specialist vasoregulatory role.  We suggest that this cytokine 
accesses the nutritive vascular tree to inhibit insulin-mediated capillary 
recruitment - a mechanism we term ‘vasocrine’ signalling. We also suggest a 
homology between this vasoactive periarteriolar fat and both periarterial and 
visceral fat, which may explain relationships between visceral fat, insulin 
resistance and vascular disease.
(169 words)Introduction
Obesity is accompanied by resistance to insulin action in skeletal muscle, 
liver and blood vessels. Insulin resistance in muscle may represent a 
mechanism to protect muscle from excessive postprandial glucose uptake in 
conditions of calorie excess.  We have suggested that low-grade 
inflammation, consequent upon the production of proinflammatory cytokines 
by adipose tissue, may underlie relationships between insulin resistance and 
vascular disease (1). We now propose that depots of fat around both large 
and small vessels may be an important source of these cytokines, and that 
periarteriolar fat plays a physiological role in regulating distribution of blood 
flow, through outside-to-inside cellular cross talk and through regional 
vascular signalling - mechanisms we term ‘vasocrine.’  Moreover, perivascular 
fat may contribute both to insulin resistance and to macrovascular disease.
Fat and Insulin Resistance - a Circulating Signal?
 Obesity decreases insulin action in liver and muscle. It is also associated 
with impaired endothelium-dependent vasodilatation, in a variety of vascular 
beds and in response to a variety of vasodilators, including insulin (2). But 
‘How does the liver/muscle/endothelium know you’re fat?’  Traditional thinking 
has been that adipocytes generate insulin resistance by producing non-
esterified fatty acids (NEFAs) which inhibit carbohydrate metabolism via 
substrate competition and impaired insulin signalling (3). The endothelial nitric 
oxide synthase (eNOS) molecule is inhibited by fatty acids (4), so NEFA may 
also provide the signal to endothelium. But other potential adipocyte signals 
are relevant. Mice with a GLUT-4 knockout located specifically to adipose tissue show insulin resistance in liver and skeletal muscle in vivo, but not in 
vitro (5) despite lower circulating NEFA concentrations - implying the 
existence of other fat-derived insulin resistance signals. Overweight subjects 
have increased levels of circulating adipocytokines, such as tumour necrosis 
factor-α (TNF-α) and interleukin-6, which may provide a pathway linking 
obesity to insulin resistance in liver, muscle and vessels (1).
Fat and Insulin Resistance - a Local Signal?
An alternative explanation has been proposed to explain hepatic and muscle 
insulin resistance in obesity - that of ectopic fat.  Accumulation of 
hepatocellular fat is associated with hepatic insulin resistance (6).  In skeletal 
muscle, insulin resistance occurs with accumulation of intramyocellular 
triglyceride (7). These findings raise the possibility that prolonged exposure of 
liver and muscle to an ‘insulin resistant milieu’ somehow generates sufficient 
intrahepatic and intramyocellular fat to produce insulin resistance in these 
target organs, perhaps through local NEFA generation, or through increased 
cytokine expression, without any ongoing circulating adipose-derived signal. 
We propose that increased adipose mass may also generate cytokine signals 
to blood vessels through the medium of perivascular fat, also ‘ectopic’ 
although within adipocytes. We suggest that the organism’s perivascular 
adipocytes act as an integrated organ responsible for paracrine and 
‘vasocrine’ signalling, which in turn contributes to skeletal muscle insulin 
resistance.The Anatomy and Physiology of Skeletal Muscle Blood Supply
Substantal data from rats (8), and more limited human studies (9,10), have 
shown insulin to have a marked and rapid effect to increase nutritive blood 
flow to skeletal muscle and skin, an effect shared, in muscle, with exercise. 
We propose that this action of insulin helps to coordinate postprandial 
delivery of substrate and hormone to insulin-sensitive tissues.  Insulin’s ability 
to recruit capillaries is likely to depend on its action in dilating precapillary 
arterioles (11). In-vitro studies we have performed in larger (so-called first 
order) arterioles from rat cremaster muscle, however, demonstrate a dual 
effect of insulin on arteriolar endothelium.  In vessels from healthy rats, insulin 
has no net effect on vessel diameter, because of a balance between 
stimulation of two pathways - nitric oxide (NO)-mediated vasodilatation and 
endothelin-1 (ET-1)-mediated vasoconstriction. Insulin stimulates eNOS 
activation, the signalling pathway being through insulin receptor substrate-1 
(IRS-1), phosphoinositol-3-kinase (PI3-K) and Akt (12,13).  However, if this 
pathway is inhibited, the arteriole constricts, a response mediated, through 
the extracellular signal-related kinase-1/2 (ERK-1/2) pathway, by endothelin-1 
(ET-1) (13).  In the cremaster muscle arteriole from a Zucker fatty rat, our 
findings show that insulin induces vasoconstriction, because of unopposed 
action of ET-1. These observations imply a dual insulin signalling mechanism 
- one pathway stimulating nitric oxide (NO) synthesis, the other endothelin-1 
release. In obesity, the ET-1 pathway dominates, insulin resistance in these 
arterioles being limited to the IRS-1/PI3-K/Akt pathway. We propose that this 
dual mechanism allows for local regulation of insulin action.The rat cremaster muscle is virtually two-dimensional, allowing observation of 
structural/functional relationships. The morphology of the muscle differs 
between lean and obese animals, with the presence of a well-circumscribed 
depot of fat around the origin of the vessel in the obese Zucker rat (Figure 1). 
This suggests an elegant regulatory mechanism. We propose that, in 
situations of chronic calorie excess or inactivity, an organism protects its 
muscle from substrate over-supply by creating a local fat pad at the vessel 
origin with specialist vasoregulatory function. Adipocytokines from these 
pads, such as TNF-α, inhibit the PI3-K signalling pathway of eNOS activation 
and NO production (14). In vivo, insulin-induced vasodilatation and nutritive 
capillary recruitment are inhibited by TNF-α (15).  These vasoregulatory fat 
depots, then, have the capacity locally to modulate the systemic vasodilating 
effects of insulin, instead producing vasoconstriction. 
We also suggest a novel mechanism to enhance the signalling function of 
TNF-α. The effects of insulin to stimulate, and of TNF-α  to inhibit, nutritive 
flow is likely to reside in recruitment or drop-out of muscle capillary networks, 
consequent upon vasodilatation or constriction in smaller, precapillary 
arterioles (11). We hypothesise that increased endothelial permeability, 
consequent upon the cytokine’s action, allows its diffusion into the lumen, 
where high concentrations may exceed the capacity of circulating binding 
proteins. This might then produce inhibition of insulin-mediated vasodilatation 
throughout the nutritive vascular tree, down to and including the precapillary 
arterioles. This could explain the observations reported above, made on 
arterioles downstream of the fat pad  and themselves free of fat (Figure 1). As these high cytokine concentrations are limited to action on vascular 
endothelium, and are unlikely to access the systemic circulation, we term this 
a ‘vasocrine’ signal. Nitric oxide may be another molecule acting in regional 
vascular beds through similar vasocrine mechanisms (16). 
Periarteriolar Fat - Vasoregulatory Function?
We hypothesise, then, that the arterial tree has evolved a sophisticated 
control mechanism to regulate postprandial substrate partition during 
conditions of calorie balance and excess. This mechanism depends on the 
contractile properties of vascular medial smooth muscle cells, which are 
under dual regulation by insulin.  One such mechanism is the synthesis of a 
vasodilator, NO, the production of which, as elegantly shown by Furchgott 
(17), requires healthy endothelial cells. We now propose that this mechanism 
is regionally modulated by adipocytokines secreted from another, adventitial, 
layer of cells, acting in paracrine and vasocrine fashion to alter insulin-
mediated NO/endothelin-1 balance (Figure 2).  In lean animals, insulin 
induces postprandial increases in nutritive flow. However with continued 
calorie excess, inactivity and obesity, vasoregulatory periarteriolar fat 
accumulates, resulting in diminished insulin-induced vasodilatation or even 
vasoconstriction (18), exacerbating muscle insulin resistance and so 
protecting it from excess substrate delivery.
Functionally, two distinct vascular circuits exist in muscle: a nutritive route 
supplying nutrients, oxygen and hormones to myocytes, and a non-nutritive 
one, which may pass through functional shunt vessels in muscle connective tissue (19).  Our hypothesis applies only to nutritive vessels, because insulin-
induced vasoconstriction of non-nutritive vessels would increase nutritive flow 
and thus insulin sensitivity.  We propose that nutritive vessels differ 
functionally from non-nutritive ones in response to insulin (dilatation versus no 
effect or constriction as the normal response), so that adipocytokines which 
inhibit insulin-induced vasodilatation will act preferentially on nutritive vessels. 
Perivascular fat - What Might It Do?
Perivascular fat is distributed widely throughout the arterial circulation.  We 
speculate that depots around the heart and the major branches of the aorta 
share homology with the vasoregulatory depots around nutritional arterioles. 
In conditions of inactivity and calorie excess, these depots enlarge, with 
potential adverse consequences - including epicardial fat (coronary arteries), 
perirenal fat (renal arteries) and pelvic fat (ilio-femoral vessels).  These 
depots may have originated during development with a physiological role in 
regulating blood flow distribution, but may become harmful in excess. 
Overproduction of adipocytokines and outside-to-inside signalling (20), may 
lead to inflammation and atherosclerosis, perhaps to coronary calcification 
and, in renal arteries, to microalbuminuria.  Finally, an epidemiological 
relationship has been noted between epicardial and visceral fat mass (21). 
Several studies have noted a higher rate of production of adipocytokines from 
visceral than from subcutaneous fat (22), suggesting a vasoregulatory 
phenotype analogous to periarteriolar fat. Visceral fat, measured as waist 
and, perhaps, neck circumference, may, then, simply provide an easily 
measured index of the body’s periarterial and periarteriolar fat.  Testing the Hypothesis
Elegance and symmetry do not, on their own, constitute proof. The rat 
cremaster muscle provides a valuable model to test the putative 
vasoregulatory role of periarteriolar fat. The study of vessels from obese rats, 
with the fat depot in situ or previously removed, and in vessels from lean 
animals exposed to perfusate from obese vessels, would provide tests of the 
vasocrine hypothesis. Inhibitors of the major insulin signalling pathways and 
monoclonal antibodies to cytokines would provide delineation of the signalling 
molecules and pathways. Additional studies, in other species and vascular 
beds, might require tissue-specific knock-outs of signalling molecules, and 
interventions physically to separate blood vessels from perivascular fat. Such 
interventions would be expected to influence vascular responsiveness, 
peripheral insulin action, and in the longer term, atherogenesis.
Conclusions
We propose that periarteriolar fat represents a physiological mechanism to 
regulate distribution of postprandial blood flow within, and perhaps between, 
organs. This regulation requires a series of locally and regionally acting 
molecules to modulate the systemic actions of insulin on NO-mediated 
vasodilatation.  However with nutritional excess and indolence, physiology 
turns to pathology - insulin resistance, microinflammation and 
macroangiopathy. These proposals remain to be tested. 
AcknowledgementsWe are grateful to our colleagues in the Vrije Universiteit Obesity Group, Prof 
Nico Westerhof, Prof Jaap Seidell, Dr Yvo Smulders and Dr Samyah Shadid 
for stimulating discussions on the mechanisms of the influence of fat on 
insulin resistance and vascular disease.
Conflict of Interest Statement
JY serves on a Scientific Advisory Board for Glaxo SmithKline.References
1. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW. C-reactive 
protein in healthy subjects: association with obesity, insulin resistance, 
and endothelial dysfunction. Arterioscleros Thromb Vasc Biol 1999; 19: 
972-978.
2. Baron AD, Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel 
G. Insulin-mediated skeletal muscle vasodilation contributes to both 
insulin sensitivity and responsiveness in lean humans. J Clin Invest 
1995; 96: 786-792. 
3. Randle PJ. Regulatory interactions between lipids and carbohydrates: 
the glucose fatty acid cycle after 35 years. Diabetes Metab Rev 1998; 
14: 263-283.
4. Davda RK, Stepniakowski KT, Lu G, Ullian ME and Goodfriend TL. 
Oleic acid inhibits endothelial nitric oxide synthase by a protein kinase 
C-independent mechanism. Hypertension 1995; 26: 764-770.
5. Abel ED, Peroni O, Kim JK, Kim YB, Boss O, Hadro E, Minnemann T, 
Shulman GI, Kahn BB. Adipose-selective targeting of the GLUT4 gene 
impairs insulin action in muscle and liver. Nature. 2001;409:729-33.
6. Seppala-Lindroos A, Vehkavaara S, Hakkinen A-M, Goto T, 
Westerbacka J, Sovijarvi A, Halavaara J and Yki-Järvinen H. Fat 
accumulation in the liver is associated with defects in insulin 
suppression of glucose production and serum free fatty acids 
independent of obesity in normal men. J Clin Endo Metab 2002; 87: 
3023-3028.
7.  Kelley DE and Mandarino LJ. Fuel selection in human skeletal muscle 
in insulin resistance: a reexamination. Diabetes 2000; 49: 677-683.
8. Zhang L, Vincent MA, Richards SM, Clerk LH, Rattigan S, Clark MG 
and Barrett EJ. Insulin sensitivity of muscle capillary recruitment in 
vivo. Diabetes 2004; 53: 447-453.
9. Coggins M, Lindner J, Rattigan S, Jahn L, Fasy E, Kaul S and Barrett 
E. 
Physiologic hyperinsulinemia enhances human skeletal muscle perfusion by 
capillary recruitment. Diabetes 2001 ; 50 : 2682-2690.
.
10.Serné EH, IJzerman RG, Gans RO, Nijveldt R, De Vries G, Evertz R, 
Donker AJ, Stehouwer CD. Direct evidence for insulin-induced capillary
recruitment in skin of healthy subjects during physiological 
hyperinsulinemia. Diabetes 2002 ; 51 : 1515-1522..
11.Greene AS, Tonellato PJ, Lui J, Lombard JH and Cowley AW. 
Microvascular rarefaction and tissue vascular resistance in hypertension. Am J Physiol (Heart Circ Physiol) 1989; 256: H126-
H131.
12. Rattigan S, Clark MG and Barrett EJ. Hemodynamic actions of insulin 
in rat skeletal muscle. Evidence for capillary recruitment. Diabetes 
1997; 46: 1381-1388.
13.Eringa EC, Sthouwer CDA, van Nieuw Amerongen GP, Ouwehand L, 
Westerhof N and Sipkema P. Vasoconstrictor effects of insulin in 
skeletal muscle arterioles are mediated by ERK1/2 activation in 
endothelium. Am J Physiol Heart Circ Physiol (Aprl 1, 2004). 
10.1152/ajpheart.00067.2004. 
14.Mohamed F, Monge JC, Gordon A, Cernacek P, Blais D and Stewart 
DJ. Lack of role for nitric oxide (NO) in the selective destabilisation of 
endothelial NO synthase mRNA by tumor necrosis factor-alpha. 
Arterioscler Thromb Vasc Biol 1995; 15: 52-57.
15.Zhang L, Wheatley CM, Richards SM, Barrett EJ, Clark MG, Rattigan 
S. TNF-alpha acutely inhibits vascular effects of physiological but not 
high insulin or contraction. Am J Physiol Endocrinol Metab. 2003; 285: 
E654-60.
16.Schechter AN and Gladwin MT. Hemoglobin and the paracrine and 
endocrine functions of nitric oxide. N Engl J Med. 2003; 348:1483-5.
17.Furchgott RF and Zawadaki JV. The obligatory role of endothelial cells 
in the relaxation of arterial smooth muscle by acetylcholine. Nature 
1980; 288: 373-376.
18.Wallis MG, Wheatley CM, Rattigan S, Barrett EJ, Clark AD and Clark 
MG. Insulin-mediated hemodynamic changes are impaired in muscle 
of Zucker obese rats. Diabetes 2002; 51: 3492-3498.
19.Newman JMB, Steen JT and Clark MG. Vessels supplying septa and 
tendons as functional shunts in perfused rat hindlimb. Microvasc Res 
1997; 54: 49-57.
20.Mazurek T, Zhang LF, Zalewski A, Mannion JD, Diehl JT, Arafat H, 
Sarov-Blat L, O’Brien S, Keiper EA, Johnson AG, Martin J, Goldstein 
BJ and Shi Y. Human epicardial adipose tissue is a source of 
inflammatory mediators. Circulation 2003; 108: 2460-2466.
21.Iacobellis G, Ribaudo MC, Assael F, Vecci E, Tiberti C, Zappaterreno 
A, Di Mario U and Leonetti F. Echocardiographic epicardial adipose 
tissue is related to anthropometric and clinical parameters of metabolic 
syndrome: a new indicator of cardiovascular risk. J Clin Endo Metab 
2003; 88: 5163-5168.
22.Arner P. Regional differences in protein production by human adipose 
tissue. Biochem Soc Trans 2001; 29 (Pt 2): 72-75.Figure 1a: Isolated cremaster muscle from Zucker fatty rat
   1b: Enlargement of origin of arteriole
a
b
  
Figure 2: Vasocrine signalling from perivascular fat
Adipocytokines secreted from perivascular adipocytes inhibit the PI3-kinase 
pathway of insulin signalling, leaving unopposed vasoconstrictor effects of 
endothelin-1. High concentrations of tumour necrosis factor-α access the 
vascular lumen, resulting in inhibition of endothelial PI3-kinase pathway 
insulin signalling in downstream vessels. Reduced insulin-mediated 
enhancement of muscle nutritive blood flow will contribute to insulin 
resistance.  EC - endothelial cell; VSMC - vascular smooth muscle cell; eNOS 
- endothelial nitric oxide synthase; NO - nitric oxide; PI3-K - phosphoinositol-
3-kinase; TNF-α - tumour necrosis factor-α; IL-6 - interleukin-6; NEFA - non-
esterified fatty acids; ERK - extracellular signal-related kinase; ET-1 - endothelin-1